Ventana and Quintiles are partnering up to provide companion diagnostic testing services in China for early clinical trials. China is among a few countries that requires patient samples used in clinical trials to be tested domestically for inclusion in the country's approval process.
Daiichi Sankyo, Japan's second-largest pharma outfit, has agreed to pay up to $650 million to get its hands on some hydrocodone combo medications, striking a deal with Charleston Laboratories with hopes of cashing in on the demand for pain pills.
Siemens and Cerner are teaming up to develop medical devices, imaging and healthcare technology as part of Cerner's $1.3 billion acquisition of Siemens' health information technology business.
Boehringer Ingelheim has handed back the rights to a drug development project targeting pain and inflammation, ending a long-standing partnership with Orexo.
As part of a broader mandate for Philips to make itself more relevant in healthcare, Royal Philips and Accenture have created proof-of-concept software to enable anyone with limited muscle or speech function to better interact with the world around them.
Columbia Laboratories has struck a deal with CRO XenoGesis to team up on preclinical research, pooling their resources to offer tandem early-phase services.
Well-heeled venture capital firm Venrock has pieced together a 7th fund, banking $450 million in new investments as it sets out to grow its portfolio of promising startups.
Sanofi and Regeneron just stole a march on Amgen in the race to get their PCSK9 cardio drug through the FDA and onto the market. The two companies revealed Wednesday evening that they had picked up a priority review voucher BioMarin had won for a recent rare disease drug approval, paying $67.5 million for the regulatory shortcut. They'll split the cost and share in the benefit, shaving four months off the regulatory review time for alirocumab.
Gilead has picked up the exclusive rights to develop a set of HIV-neutralizing antibodies discovered at Theraclone in collaboration with the International AIDS Vaccine Initiative and The Scripps Research Institute. Seattle-based Theraclone, which used its tech platform I-STAR in the project, picked up an unspecified set of milestones and an upfront payment in the deal.
Japanese tech giant Konica Minolta sealed an agreement with a New Jersey diagnostics outfit to develop a test that can rapidly detect early cardiac muscle tissue damage after heart attacks strike.